Nuvo (AMEX:NUVO)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Nuvo Charts. Click Here for more Nuvo Charts.](/p.php?pid=staticchart&s=A%5ENUVO&p=8&t=15)
Nuvelo Announces Completion of Common Stock Offering
SUNNYVALE, Calif., March 8 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq:
NUVO; NUVOD) today announced the completion of its public offering of 5,000,000
shares of common stock and the additionalsale of 750,000 shares pursuant to the
exercise of an over-allotment option granted to the underwriters. Including the
sale of these additional shares, the offering was for 5,750,000 shares of common
stock at $13.00 per share, resulting in total gross proceeds of approximately
$74.8 million.
UBS Securities LLC acted as the sole book-running manager in this offering. CIBC
World Markets Corp., Needham & Company, Inc. and JMP Securities LLC acted as
co-managers.
A shelf registration statement relatingto these securities was originally filed
with the Securities and Exchange Commission on January 26, 2004 and has since
been declared effective. This press release does not constitute an offer to sell
or the solicitation of an offer to buy any of the securities, nor shall there be
any sale of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any jurisdiction. This offering of
shares of common stock was made only by means of a prospectus supplement and
accompanying prospectus. Copies of the prospectus supplement and the
accompanying prospectus can be obtained from UBS Securities LLC, ECMG Syndicate,
299 Park Avenue, New York, NY 10171.
About Nuvelo
Nuvelo, Inc. is engaged in the discovery, development and commercialization of
life improving therapeutics for the treatment of human disease. Nuvelo's lead
product candidate, alfimeprase, is partnered with Amgen and is currently in two
Phase 2 trials in two indications, peripheral arterial occlusion and catheter
occlusion. Additional programs include cardiovascular product candidates ARC183
and rNAPc2 and drug discovery focused on antibody targets and secreted
proteins.
Informationabout Nuvelo is available at our new Web site at
http://www.nuvelo.com/ or by phoning 408-215-4000.
Statements contained in this press release which are not historical in nature,
are intended to be, and are hereby identified as "forward-looking statements"
for purposes of the safe harbor provided by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements may be identified by words such
as "believe," "expect," "anticipate," "should," "may," "estimate," "goals," and
"potential," among others. Such statements are based on our management's current
expectations and involve risks and uncertainties. Actual results and performance
could differ materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, uncertainties
relating to drug discovery, clinical development processes and the development
and commercialization of our molecular diagnostics technology; changes in
relationships with strategic partners and dependence upon strategic partners for
the performance of critical activities under collaborative agreements; the
impact of competitive products and technological changes; uncertainties relating
to patent protection and regulatory approval; and uncertainties relating to our
ability to obtain substantial additional funds required for progress in drug
discovery and development. These and other factors are identified and described
in more detail in Nuvelo and Hyseq filings with the SEC, including without
limitation Nuvelo's annual report on Form 10-K and the related Form 10-K/A for
the year ended December 31, 2002 and Nuvelo's quarterly report on Form 10-Q for
the quarter ended September 30, 2003. We disclaim any intent or obligation to
update these forward-looking statements.
DATASOURCE: Nuvelo, Inc.
CONTACT: Pete Garcia, Sr. VP and Chief Financial Officer,
+1-408-215-4574, or , or Nicole Estrin, Manager of Corporate
Communications & IR, +1-408-215-4572, or , both of Nuvelo,
Inc.
Web site: http://www.nuvelo.com/